Treatment of diabetic rats with encapsulated islets

Immunoprotection of islets using bioisolator systems permits introduction of allogeneic cells to diabetic patients without the need for immunosuppression. Using TheraCyte™ immunoisolation devices, we investigated two rat models of type 1 diabetes mellitus (T1DM), BB rats and rats made diabetic by streptozotocin (STZ) treatment. We chose to implant islets after the onset of diabetes to mimic the probable treatment of children with T1DM as they are usually diagnosed after disease onset. We encapsulated 1000 rat islets and implanted them subcutaneously (SQ) into diabetic biobreeding (BB) rats and STZ‐induced diabetic rats, defined as two or more consecutive days of blood glucose >350 mg/dl. Rats were monitored for weight and blood glucose. Untreated BB rats rapidly lost weight and were euthanized at >20% weight loss that occurred between 4 and 10 days from implantation. For period of 30–40 days following islet implantation weights of treated rats remained steady or increased. Rapid weight loss occurred after surgical removal of devices that contained insulin positive islets. STZ‐treated rats that received encapsulated islets showed steady weight gain for up to 130 days, whereas untreated control rats showed steady weight loss that achieved >20% at around 55 days. Although islet implants did not normalize blood glucose, treated rats were apparently healthy and groomed normally. Autologous or allogeneic islets were equally effective in providing treatment. TheraCyte™ devices can sustain islets, protect allogeneic cells from immune attack and provide treatment for diabetic‐mediated weight loss in both BB rats and STZ‐induced diabetic rats.

[1]  D. Trono,et al.  Lentivirus-mediated Bcl-2 expression in βTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion , 1999, Gene Therapy.

[2]  A. Sambanis,et al.  Effects of Short-Term Hypoxia on a Transformed Cell-Based Bioartificial Pancreatic Construct , 2000, Cell transplantation.

[3]  C. Ricordi,et al.  Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors1 , 2003, Transplantation.

[4]  C. Newgard,et al.  While tinkering with the beta-cell...metabolic regulatory mechanisms and new therapeutic strategies: American Diabetes Association Lilly Lecture, 2001. , 2002, Diabetes.

[5]  B A Solomon,et al.  Biohybrid artificial pancreas: long-term implantation studies in diabetic, pancreatectomized dogs. , 1991, Science.

[6]  C. Ricordi,et al.  Adenoviral gene transfer of erythropoietin confers cytoprotection to isolated pancreatic islets , 2004, Transplantation.

[7]  W. Hagopian,et al.  Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. , 2002, Diabetes care.

[8]  Y. Byun,et al.  Improved phenotype of rat islets in a macrocapsule by co-encapsulation with cross-linked Hb , 2005, Journal of biomaterials science. Polymer edition.

[9]  G. Leibowitz,et al.  Towards gene therapy of diabetes mellitus. , 1999, Molecular medicine today.

[10]  J. Callis,et al.  Regulation of ATP/ADP in pancreatic islets. , 2004, Diabetes.

[11]  S. Sigrist,et al.  Influence of VEGF on the Viability of Encapsulated Pancreatic Rat Islets after Transplantation in Diabetic Mice , 2003, Cell transplantation.

[12]  A. Sambanis,et al.  Non‐Invasive Monitoring of a Bioartificial Pancreas in Vitro and in Vivo , 2001, Annals of the New York Academy of Sciences.

[13]  E. Ryan,et al.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.

[14]  H. Noushmehr,et al.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.

[15]  A. Gaber,et al.  Glucose Stimulation of Cytochrome C Reduction and Oxygen Consumption as Assessment of Human Islet Quality , 2005, Transplantation.

[16]  C. Newgard,et al.  Use of recombinant adenovirus for metabolic engineering of mammalian cells. , 1994, Methods in cell biology.

[17]  P. Arner,et al.  In Vivo Evaluation of Glucose Permeability of an Immunoisolation Device Intended for Islet Transplantation: A Novel Application of the Microdialysis Technique , 1999, Cell transplantation.

[18]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[19]  Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. , 1998, Annals of internal medicine.

[20]  O. Yanay,et al.  Long-term erythropoietin gene expression from transduced cells in bioisolator devices. , 2003, Human gene therapy.

[21]  Eric S Lander,et al.  Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. , 2002, Genome research.

[22]  M. Trucco,et al.  Targeting autoimmune diabetes with gene therapy. , 1999, Diabetes.

[23]  J. Nordenström,et al.  Survival of Macroencapsulated Allogeneic Parathyroid Tissue One Year after Transplantation in Nonimmunosuppressed Humans , 2001, Cell transplantation.

[24]  Å. Lernmark,et al.  Rel B is an early marker of autoimmune islet inflammation in the biobreeding (BB) rat. , 2000, Pancreas.

[25]  Darrell M. Wilson,et al.  Duration of Nocturnal Hypoglycemia Before Seizures , 2008, Diabetes Care.

[26]  S. Lenzen,et al.  Recovery of Pancreatic &bgr; Cells in Response to Long-term Normoglycemia After Pancreas or Islet Transplantation in Severely Streptozotocin Diabetic Adult Rats , 2001, Pancreas.

[27]  S. Kreiner,et al.  Mortality of Type 1 (insulin-dependent) diabetes mellitus in Denmark: A study of relative mortality in 2930 Danish type 1 diabetic patients diagnosed from 1933 to 1972 , 1986, Diabetologia.

[28]  D. Drucker,et al.  Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. , 2003, Diabetes.

[29]  C. Ricordi,et al.  Reversal of Diabetes by Pancreatic Islet Transplantation into a Subcutaneous, Neovascularized Device , 2006, Transplantation.

[30]  I. Sweet,et al.  Contribution of Calcium Influx in Mediating Glucose-Stimulated Oxygen Consumption in Pancreatic Islets , 2006, Diabetes.

[31]  R. Rubin,et al.  Implications of the DCCT: Looking beyond tight control , 1994, Diabetes Care.

[32]  F T Gentile,et al.  Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. , 1991, Science.

[33]  C. Alpers,et al.  Animal Model Cryoglobulinemic Glomerulonephritis in Thymic Stromal Lymphopoietin Transgenic Mice , 2001 .

[34]  A. Sambanis,et al.  Development of a bioartificial pancreas: II. Effects of oxygen on long-term entrapped betaTC3 cell cultures. , 1999, Biotechnology and bioengineering.

[35]  R. C. Johnson,et al.  Correction of diabetic nod mice with insulinomas implanted within Baxter immunoisolation devices , 1999, Journal of Molecular Medicine.

[36]  G. Steil,et al.  Improved Vascularization of Planar Membrane Diffusion Devices following Continuous Infusion of Vascular Endothelial Growth Factor , 2000, Cell transplantation.

[37]  T. Mandrup-Poulsen,et al.  On the Pathogenesis of Insulin-Dependent Diabetes Mellitus — A Discussion of Three Recently Proposed Models , 1989 .

[38]  C. Colton,et al.  Effect of Hypoxia on Insulin Secretion by Isolated Rat and Canine Islets of Langerhans , 1993, Diabetes.

[39]  E. Lander,et al.  Genetic isolation of iddm 1 on Chromosome 4 in the BioBreeding (BB) rat , 1998, Mammalian Genome.

[40]  Y. Bae,et al.  Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets. , 2005, Biomaterials.

[41]  R. C. Johnson,et al.  In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices , 1999, Journal of Molecular Medicine.

[42]  J. Callis,et al.  Continuous measurement of oxygen consumption by pancreatic islets. , 2002, Diabetes technology & therapeutics.

[43]  S. Ramanathan,et al.  BB rat lyp mutation and Type 1 diabetes , 2001, Immunological reviews.

[44]  C. Colton,et al.  Effect of External Oxygen Mass Transfer Resistances on Viability of Immunoisolated Tissue a , 1997, Annals of the New York Academy of Sciences.